XOMA Royalty (NASDAQ:XOMA) Upgraded to "Strong-Buy" at Zacks Research

Key Points

• XOMA Royalty was upgraded to a Strong-Buy rating by Zacks Research, reflecting increased confidence in the stock's performance.
• The company reported $0.48 earnings per share for the recent quarterly earnings, surpassing analyst expectations significantly.
• Institutional investors own approximately 95.92% of XOMA Royalty's stock, indicating strong institutional interest and support for the company.

Zacks Research upgraded shares of XOMA Royalty (NASDAQ:XOMA - Free Report) from a hold rating to a strong-buy rating in a research report released on Wednesday,Zacks.com reports.

Several other research firms also recently commented on XOMA. Wall Street Zen raised shares of XOMA Royalty from a "hold" rating to a "buy" rating in a research report on Monday, August 11th. HC Wainwright reissued a "buy" rating and set a $104.00 target price on shares of XOMA Royalty in a research report on Wednesday, May 28th. One equities research analyst has rated the stock with a Strong Buy rating and two have issued a Buy rating to the company's stock. According to MarketBeat, the company has a consensus rating of "Buy" and a consensus target price of $69.50.

XOMA Royalty Trading Up 1.2%

XOMA stock traded up $0.44 during midday trading on Wednesday, hitting $37.86. The stock had a trading volume of 27,011 shares, compared to its average volume of 45,035. The firm has a market cap of $457.73 million, a P/E ratio of -24.43 and a beta of 0.98. The company has a current ratio of 4.88, a quick ratio of 4.88 and a debt-to-equity ratio of 1.41. XOMA Royalty has a 1-year low of $18.35 and a 1-year high of $38.00. The business has a fifty day moving average price of $29.90 and a two-hundred day moving average price of $25.57.

XOMA Royalty (NASDAQ:XOMA - Get Free Report) last released its earnings results on Wednesday, August 13th. The biotechnology company reported $0.48 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.12) by $0.60. The business had revenue of $13.13 million for the quarter, compared to analyst estimates of $9.39 million. XOMA Royalty had a negative net margin of 27.57% and a positive return on equity of 2.63%. On average, sell-side analysts predict that XOMA Royalty will post -1.41 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the stock. GAMMA Investing LLC lifted its stake in shares of XOMA Royalty by 1,063.8% during the 1st quarter. GAMMA Investing LLC now owns 1,734 shares of the biotechnology company's stock valued at $35,000 after buying an additional 1,585 shares in the last quarter. Tower Research Capital LLC TRC lifted its stake in shares of XOMA Royalty by 203.1% during the 2nd quarter. Tower Research Capital LLC TRC now owns 2,273 shares of the biotechnology company's stock valued at $57,000 after buying an additional 1,523 shares in the last quarter. JPMorgan Chase & Co. lifted its stake in shares of XOMA Royalty by 13.9% during the 2nd quarter. JPMorgan Chase & Co. now owns 4,440 shares of the biotechnology company's stock valued at $112,000 after buying an additional 543 shares in the last quarter. Raymond James Financial Inc. purchased a new stake in XOMA Royalty in the 2nd quarter worth approximately $116,000. Finally, Deutsche Bank AG lifted its stake in XOMA Royalty by 5,087.9% in the 1st quarter. Deutsche Bank AG now owns 6,433 shares of the biotechnology company's stock worth $128,000 after purchasing an additional 6,309 shares in the last quarter. 95.92% of the stock is owned by institutional investors.

XOMA Royalty Company Profile

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.